Wockhardt provides update on step down subsidiary in UK - C P Pharmaceuticals

C P Pharmaceuticals gets warning letter from USFDA

Wockhardt announced that U.S. Food and Drug Administration ('USFDA') has issued a Warning Letter to C P Pharmaceuticals, Wrexham, United Kingdom, a stepdown Subsidiary of the Company.

Currently, there is no business being conducted from C P Pharmaceuticals to the US Market. C P Pharmaceuticals has already initiated required steps to address the concerns raised by USFDA and will be responding to the Agency within the prescribed time.

Powered by Capital Market - Live News